IACS‐010759 is another clinical grade CI inhibitor derived from compounds able to reduce HIF‐1 response and to inhibit proliferation of neoplasms of the nervous system and acute myeloid leukemia (AML) derived glycolysis‐defective cells, in which the inhibition of CI promptly triggered apoptosis [131]. This evidence concerns the gene HIF1A and acute myeloid leukemia.